12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Canagliflozin: Phase III data

The double-blind, international Phase III DIA3005 trial in 584 Type II diabetics inadequately controlled with diet and exercise showed that once-daily 100 and 300 mg oral canagliflozin each met the primary endpoint of reducing HbA1c from baseline to week 26 vs. placebo (placebo-adjusted reductions of 0.91% and 1.16%, respectively, p<0.001 for both). On secondary endpoints, low- and high-dose canagliflozin led to significantly greater placebo-adjusted reductions in FPG (1.97 and 2.41 mmol/L, p<0.001 for both), 2-hour post-prandial plasma glucose (2.67 and...

Read the full 379 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >